Recipient of Melanoma Drug in Development Celebrates Two Cancer-Free Years
Posted on: Tuesday, 16 October 2007, 06:00 CDT
KNOXVILLE, Tenn., Oct. 16 /PRNewswire/ -- When eighty-six-year-old Keith Hora went to see Dr. Peter Hersey, a medical oncologist and professor at the University of Newcastle in Australia, he was told he only had three to six months to live. Hora had been diagnosed with stage III melanoma, one of the most difficult to treat forms of cancer.
"Mr. Hora had multiple melanoma reoccurrences in the previously treated area of his face and nothing was helping him, including multiple surgeries to remove the tumors as well as radiation therapy," recalls Dr. Hersey, a fifteen-year member of the World Health Organization's committee on Melanoma. "His tumors kept returning."
Hora was included in a Phase 1 clinical trial of PV-10 conducted by Dr. Hersey. The trials were sponsored by Knoxville, TN-based Provectus Pharmaceuticals. PV-10 is a small molecule oncology agent being investigated by Provectus for treatment of melanoma and other focal forms of cancer.
"When it is injected into tumor tissue, the drug concentrates in the tumor at cytotoxic levels while quickly dissipating from healthy tissue," says Dr. Hersey. "This makes it safer and more effective than some other therapies."
Hora was treated in late 2005 and recalled getting the good news a few weeks later during an ultrasound follow-up that determined the tumors were shrinking. "After being cancer-free for two years, I feel like jumping over a moon," says Hora.
Provectus has begun the next round of testing intended to demonstrate definitively the efficacy of PV-10. The Phase 2 trial will treat up to eighty Stage III/IV melanoma patients at seven or more sites in Australia and the U.S. While PV-10 is currently undergoing clinical trials to treat melanoma and breast cancer, in pre-clinical testing the drug has been shown to kill many other types of cancer. Additional clinical testing for treatment of primary and metastatic liver cancers is expected to begin later this year or early in 2008.
For more information, log on to http://www.pvct.com/.
Provectus Pharmaceuticals
CONTACT: Janet Vasquez of IRG, +1-212-825-3210, for ProvectusPharmaceuticals
Web site: http://www.pvct.com/
Source: PRNewswire
Related Articles
- Depression In Older Cancer Patients Can Be Effectively Treated With Collaborative Approach
- Researcher Develops Dissolving Strips For Clinical Taste Tests
- New Pfizer Data in Lung Cancer, Ewing's Sarcoma, Prostate Cancer and Other Difficult-to-Treat Tumor Types to Be Presented at ASCO
- Siemens and LabCorp Enter Agreement to Co-Develop New Clinical Diagnostic Tests
- Clinical Laboratory Analysis Is One of the Most Important Sections of Medical Care Which Is a Significant Reason to Get a Hold of Clinical Laboratory Testing Volume 2: Business Strategies
- The Major Clinical Testing Companies Estimate the Annual Market for Their Services to Be More Than $40 Billion - 'Clinical Laboratory Testing Market Overview 2006'
- This Clinical Laboratory Testing Market Overview Provides the Information and Analysis You Need to Gain an Understanding of the Clinical/Diagnostic Testing Market and the Trends Which Affect It
- New CT Scanner Specifically Designed for Cancer Patients Lets Physicians Locate, Treat Tumors More Accurately
- Peregrine Pharmaceuticals Opens Patient Enrollment for Its Tarvacin(TM) Phase I Solid Cancer Therapy Clinical Trial
- Breast-Cancer Frauds Dupe Doctors into Treating Them
 |
 |
User Comments (0)
RSS Feeds